期刊文献+

IL-6与肿瘤耐药相关性的研究进展 被引量:7

Research advances in the relationship between IL-6 and malignant tumor drug-resistance
原文传递
导出
摘要 肿瘤对化疗药物耐药性的产生是造成治疗失败的主要因素。形成肿瘤耐药的机制很复杂。IL-6作为一种重要的炎性细胞因子与恶性肿瘤细胞对化疗药物耐药性密切相关。IL-6极有可能成为逆转某些恶性肿瘤耐药性的新靶点。 ] The emergence of drug resistance of tumors to chemotherapeutic drugs is the main cause of treatment failure. The mech- anism of tumor resistance is very complex. IL-6, as one of the important inflammatory cytokines, is closely related to the chemotherapy drug resistance of malignant cells. IL-6 is likely to become a new target for the reversal of the drug resistance of some malignant tumors.
出处 《中国微生态学杂志》 CAS CSCD 2013年第9期1111-1113,共3页 Chinese Journal of Microecology
关键词 IL-6 肿瘤耐药 IL-6 Tumor drug-resistant
  • 相关文献

参考文献21

  • 1LIU hui, ZHU bo, LIN zhi-hua. IL-6 signal pathways and malignanttumor[ J]. Chin J Cell Mol Immunol,2011,27(3) :353-355. 被引量:1
  • 2刘徽,朱波,林治华.IL-6信号通路与肿瘤[J].细胞与分子免疫学杂志,2011,27(3):353-355. 被引量:55
  • 3Kishimoto T. Interleukin-6:from basic science to medicine-40 years inimmunology[ J]. Annu Rev Immunol,2005,23 :1 -21 ?. 被引量:1
  • 4HodgeDR,Hurt EM,FarrarWL. The role of IL-6 and STAT3 in inflam-mation and cancer[ J]. Eur J Cancer,2005 ,41 ( 16) :2502-2512. 被引量:1
  • 5TchirkovA,Khalil T,Chautard E,e t al. Interleukin-6 gene amplifica-tion and shortened survival in glioblastoma patients [ J]. Br J Cancer,2007,96(3) :474476. 被引量:1
  • 6LIAN Li-juan, LIN Qiao-zhi. Gynecologic oncology [ M]. 3rd ed. Bei-jing.-People's Health Publishing House,2000:410-424. 被引量:1
  • 7连利娟,林巧稚.妇科肿瘤学[M].3版.北京:人民卫生出版社,2000:288. 被引量:10
  • 8DUAN Zhen-feng, Feller AJ,Penson RT,et al. Discovery of differential-ly expressed genes associated with paclitaxel resistance using cDNA ar-ray technology: analysis of interleukin (IL) 6,IL-8,and monocyte chem-otactic protein 1 in the paclitaxel-resistant phenotype [ J]. Clin CancerRes,1999,5( 11) :3445-3453. 被引量:1
  • 9WANG Yue,NIU Xiu-long,QU Ye,et al. Autocrine production of inter-leukin-6 confers cisplatin and paclitaxel resistance in ovarian cancercells[ J]. Cancer Lett,2010,295(1 ) :110-123. 被引量:1
  • 10Duan Z, Brakra KA, Seiden MV. Inhibitian of ABOB1 ( MDR1 ) andABCD4 ( MDR3) expression by small int rfering RNA and reversal ofpaclitexel resistance in human ovarian cancer cells[ J]. Mol Cancer T-her,2004,3(7) :833-838. 被引量:1

二级参考文献14

  • 1Kishimoto T. Interleukin-6: from basic science to medicine: 40 years in immunology[J]. Annu Rev Immunol, 2005, 23:1 -21. 被引量:1
  • 2Hodge DR, Hurt EM, Farrar WL. The role of IL6 and STAT3 in inflammation and cancer[J]. Eur J Cancer, 2005, 41:2502 -2512. 被引量:1
  • 3Tchirkov A, Khalil T, Chautard E, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients[ J]. Br J Cancer, 2007, 96:474-476. 被引量:1
  • 4Qiaoling S, Qiuyang L, Yuanyuan Z, et al. Rapamycin suppresse TLR4-triggered IL-6 and PGE2 production of colon cancer cells by in hibiting TLR4 expression and NF-KB activation [ J]. J Molecular Immunology, 2008, 45 (10) : 2929 - 2936. 被引量:1
  • 5Tehirkov A, Khalil T, Chautard E, et al. lnterleukin-6 gene amplification and shortened survival in glioblastoma patients[ J]. Br J Cancer, 2007, 96:474-476. 被引量:1
  • 6Weissenberger J, Loeffler S, Kappeler A, et al. IL6 is required for glioma development in a mouse model [ J ]. Oncogene, 2004, 23: 3308-3316. 被引量:1
  • 7Wang H, Justin D, Qiulian Wu, et al. Targeting leukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth[ J]. J Cane Stem Cell, 2009, 27 : 2393 - 2404. 被引量:1
  • 8Bollrath J, Phesse TJ, van Burstin VA, et al. gpl30-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis [ J ]. Cancer Cell, 2009, 15 : 91 - 102. 被引量:1
  • 9Brooke A, Kian-Huat Lim, Christopher M. Counter. Oncogenic Rasinduced secretion of IL6 is required for tumorigenesis[ J]. J Genes & Development, 2007, 21 : 1714 - 1719. 被引量:1
  • 10Greten F, Eekmann L, Greten T, et al. IKKI3 links inflammation and tumorigenesis in a mouse model of colitis-associated cancer[ J]. J Cell, 2004, 118(3) : 285 -296. 被引量:1

共引文献63

同被引文献67

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部